Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: Looking for the grail

Medicinal Research Reviews

Volumn 27, Issue 4, 2007, Pages 574-590

  Juillerat Jeanneret, L ^a   Schmitt, F ^a  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Blood brain barrier; Cancer; Drug targeting; Folic acid; Nanoparticles

Indexed keywords

ADENOSINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BOSENTAN; CELL ADHESION MOLECULE; CELL RECEPTOR; DENDRIMER; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; DOXORUBICIN; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FOLATE RECEPTOR; GEFITINIB; GLUCOSE TRANSPORTER; IMATINIB; IRINOTECAN; MACROGOL; MELPHALAN; MONOCARBOXYLATE TRANSPORTER; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; PROTEINASE; PUTRESCINE; TRANSFERRIN RECEPTOR; TRIACYLGLYCEROL LIPASE; TRYPSIN; UNINDEXED DRUG; VALSARTAN;

ACTIVE TRANSPORT; BIODEGRADABILITY; BLOOD BRAIN BARRIER; BREAST CARCINOGENESIS; CANCER CELL; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; COLON CARCINOMA; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; DRUG TRANSPORT; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MACROPHAGE; MICROENCAPSULATION; MYELOID LEUKEMIA; NANOCHEMISTRY; NANOENCAPSULATION; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CARCINOMA; RESPIRATORY DISTRESS; REVIEW;

BLOOD-BRAIN BARRIER; BRAIN DISEASES; CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 34250791484     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20086     Document Type: Review

References (124)

1. Sharman WM, van Lier JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv Drug Deliv Rev 2004;56:53-76.
2. van Dongen GAMS, Visser GWM, Vrouenraets MB. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv Drug Deliv 2004;56:31-52.
3. Rosenkranz AA, Jans DA, Sobolev AS. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol Cell Biol 2000;78:452-464.
4. Dozzo P, Koo MS, Berger S, Forte TM, Kahl SB. Synthesis, characterization and plasma lipoprotein association of a nuclear-targeted boronated porphyrin. J Med Chem 2005;48:357-359.
5. Berger Y, Ingrassia L, Neier R, Juillerat-Jeanneret L. Evaluation of dipeptide-derivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy. Bioorg Med Chem 2003;11:1343-1351.
6. McMurray J, Cohen-Solal A, Dietz R, Eichhom E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 2005;7:710-721.
7. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmol Exp Ther 2005; 315:971-979.
8. Arap W, Pasqualini R, Ruoshlati E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-380.
9. Molema G, Meijer DKF, de Leij LFMH. Tumor vasculature targeted therapies. Biochem Pharm 1998; 55:1939-1945.
10. Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 1997;73:865-870.
11. Chen QR, Zhang L, Gasper W, Mixson AJ. Targeting tumor angiogenesis with gene therapy. Mol Gent Metab 2001;74:120-127.
12. Hood JD, Bednarski M, Frausto R, Guccione S, Resifeld RA, Xiang R, Cheresh DA. Tumor regression by targeted gene delivery to the vasculature. Science 2002;296:2404-2407.
13. Reynolds AR, Moghimi SM, Hodivala-Dilke K. Nanoparticle-mediated gene delivery to tumor vasculature. Trends Mol Med 2003;9:2-4.
14. Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004;27:559-605.
15. Provencher S, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension with bosentan: From pathophysiology to clinical evidence. Exp Op Pharmacother 2005;6:1337-1348.
16. Young TE. Postnatal steroid therapy in neonates. Curr Op Ped 1997;9:184-188.
17. Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. Exp Op Pharmacother 2005;6:985-993.
18. Koch AM, Reynolds F, Merkle HP, Weissleder R, Josephson L. Transport of surface-modified nanoparticles through cell monolayers. Chembiochem 2005;6:337-345.
19. Lu Y, Chen SC. Micro- and nano-fabrication of biodegradable polymers for drug delivery. Adv Drug Deliv Rev 2004;56:1621-1633.
20. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharm Rev 2001;53:283-318.
21. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects. FASEB J 2005;19:311-330.
22. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785-796.
23. Shenoy VS, Vijay IK, Murthy RS. Tumour targeting: Biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol 2005;57:411-422.
24. Solaro R, Chiellini F, Signori F, Fiumi C, Bizzarri R, Chiellini E. Nanoparticle systems for the targeted release of active principles of proteic nature. J Mat Sci Mat Med 2003;14:705-711.
25. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145-160.
26. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005;26:2713-2711.
27. Xia X, Hu Z, Marquez M. Physically bonded nanoparticle networks: A novel drug delivery system. J Control Release 2005;103:21-30.
28. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? PSTT 1999;2:441-449.
29. Ito S, Fukusako T, Nemoto T, Sekihara H, Seyama Y, Kubota S. Coexpression of glucose transporter and matrix metalloproteinase-2 in human cancers. J Nat Cancer Inst 2002;94:1080-1091.
30. Mizuno N, Niwa T, Yotsumoto Y, Sigiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003;55:425-461.
31. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15:300-310.
32. Tung CH, Lin Y, Moon WK, Weissleder R. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochemistry 2002;3:784-786.
33. Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharm Ther 1999;83:67-123.
34. Savellano MD, Hasan T. Photochemical targeting of epidermal growth factor receptor: A mechanistic study. Clin Cancer Res 2005;11:1658-1668.
35. Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002;1572:285-293.
36. Hakamori S. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Nat Acad Sci USA 2002;99:10231-10233.
37. Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm 2004;58:327-341.
38. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br J Biomed Sci 1999; 56:285-292.
39. Hilt JZ, Byrne ME. Configurational biomimesis in drug delivery: Molecular imprinting of biologically significant molecules. Adv Drug Deliv Rev 2004;56:1599-1620.
40. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR. Nanoparticles targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65:5317-5324.
41. Lu ZR, Shiah JG, Sakuma S, Kopechova P, Kopechek J. Design of novel bioconjugates for targeted drug delivery. J Control Release 2002;78:165-173.
42. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-685.
43. Pasqualini R, Koivunen E, Ruoshlati E. av integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-546.
44. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev 2004;56:1023-1050.
45. De Groot FM, Damen EW, Scheeren HW. Anticancer prodrug for application in monotherapy:targeting hypoxia, tumor-associated enzymes, and receptors. Cur Med Chem 2001;8:1093-1122.
46. Etrych T, Jelinkova M, Lhova B, Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: Synthesis and preliminary in vitro and in vivo biological properties. J Control Release 2001;73:89-102.
47. Leroux JC, Roux E, LeGarrec D, Hong K, Drummond DC. N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J Control Release 2001;72: 71-84.
48. Rehor A, Hubbell JA, Tirelli N. Oxidation-sensitive polymeric nanoparticles. Langmuir 2005;21:411-417.
49. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-360.
50. Davis SS. Biomedical applications of nanotechnology - implications for drug targeting and gene therapy. Trends Biotechnol 1997;15:217-224.
51. Oh KS, Lee KE, Han SS, Cho SH, Kim D, Yuk SH. Formation of core/shell nanoparticles with a lipid core and their application as a drug delivery system. Biomacromol 2005;6:1062-1067.
52. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Cur Med Chem 2004;11:413-424.
53. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer 2005;5:161-171.
54. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303:1818-1822.
55. van Nostrum CF. Polymeric micelles to deliver photosensitizers for photodynamic therapy. Adv Drug Deliv Rev 2004;56:9-16.
56. Derycke AS, de Witte PA. Liposomes for photodynamic therapy. Adv Drug Delivery Rev 2004;56: 17-30.
57. Cammas S, Bear MM, Moine L, Escalup R, Ponchel G, Kataoka K, Guerin P. Polymers of malic acid and 3-alkylmalic acid as synthetic PHAs in the design of biocompatible hydrolyzable devices. Int J Biol Macromol 1999;25:273-282.
58. Cammas S, Nagasaki Y, Kataoka K. Heterobifunctional poly(ethylene oxide): Synthesis of alpha-methoxy-omega-amino and alpha-hydroxy-omega-amino PEOs with the same molecular weights. Bioconj Chem 1995;6:226-230.
59. Grazia Cascone M, Zhu Z, Borselli F, Lazzeri L. Poly(vinyl alcohol) hydrogels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles. J Mat Sci Mat Med 2002;13:29-32.
60. Martinez Barbosa ME, Cammas S, Appel M, Ponchel G. Investigation of the degradation mechanisms of poly(malic acid) esters in vitro and their related cytotoxicities on J774 macrophages. Biomacromolecules 2004;5:137-143.
61. Missirlis D, Tirelli N, Hubbell JA. Amphiphilic hydrogel nanoparticles. Preparation, characterization, and preliminary assessment as new colloidal drug carriers. Langmuir 2005;21:2605-2613.
62. Rossignol H, Bousta M, Vert M. Synthetic poly(beta-hydroxyalkanoates) with carboxylic acid or primary amine pendent groups and their complexes. Int J Biol Macromol 1999;25:255-264.
63. Lee KB, Yoon KR, Woo SI, Choi IS. Surface modification of poly (glycolic acid) (PGA) for biomedical applications. J Pharm Sci 2003;92:933-937.
64. Nagasaki Y, Kutsuna T, Iijima M, Kato M, Kataoka K, Kitano S, Kadoma Y. Formyl-ended heterobifunctional poly(ethylene oxide) synthesis of poly(ethylene oxide)with a formyl group at one end and a hydroxyl group at the other end. Bioconjugate Chem 1996;6:231-233.
65. Shao H, Zhang Q, Goodnow R, Chen L, Tam S. A new polymer-bound N-hydroxysuccinimidyl active ester linker. Tetrahedron Lett 2000;41:4257-4260.
66. Marschütz MK, Veronese FM, Bernkop-Schnurch A. Influence of the spacer on the inhibitory effect of different polycarbophil-protease inhibitor conjugates. Eur J Pharm Biopharm 2001;52:137-144.
67. Bhavane R, Karathanasis E, Annapragada AV. Agglomerated vesicle technology: A new class of particles for controlled and modulated pulmonary drug delivery. J Control Release 2003;93:15-28.
68. Suzawa T, Nagamura S, Saito H, Ohta S, Hanai N, Kanazawa J, Okabe M, Yamasake M. Enhanced tumor cell selectivity of adriamycin monoclonal antibody conjugate via a poly(ethylene glycol)based cleavable linker. J Control Release 2002;79:229-242.
69. Reents R, Jeyaraj DA, Waldmann H. Enzymatically cleavable linker groups in polymer-supported synthesis. Drug Discov Today 2002;7:71-76.
70. Schoenmakers RG, van de Wetering P, Elbert DL, Hubbell JA. The effect of the linker on the hydrolysis rate of drug-linked ester bonds. J Control Release 2004;95:291-300.
71. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-1659.
72. Inuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002;99:130-137.
73. Panyam J, Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 2004;1:77-84.
74. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 2002;16:1217-1226.
75. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003;300:615-618.
76. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10:310-315.
77. Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 2005;26:2685-2694.
78. Tu RS, Tirrell M. Bottom-up design of biomimetic assemblies. Adv Drug Deliv Rev 2004;56:1537-1563.
79. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Progr Drug Res 2003;61:39-78.
80. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000;89:1371-1388.
81. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosc Nanotech 2004;4:484-488.
82. Pardridge WM. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 2003;3:90-105.
83. Egleton RD, Mitchell SA, Huber JD, Palian MM, Polt R, Davis TP. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J Pharmacol Exp Ther 2001;299:967-972.
84. Palian MM, Boguslasky VI, O'Brien DF, Polt R. Glycopeptide-membrane interactions: Glycosyl enkephalin analogues adopt turn conformation by NMR and Cd in amphipatic media. J Am Chem Soc 2003;125:5823-5831.
85. 111In chelation, conjugation to blood-brain barrier delivery vector via a biotin polyethylene linker, pharmacokinetics and in vivo imaging of experimental brain tumors. Bioconj Chem 1999;10:502-511.
86. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of neurotrophin. Brain Res 2001;889:49-56.
87. Juillerat-Jeanneret L, Lohm S, Hamou MF, Pinet F. Regulation of aminopeptidase A in human brain tumor vasculature: Evidence for a role of TGF-β. Lab Invest 2000;80:973-980.
88. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2005;2:44-53.
89. Abulrob A, Sprong H, van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating sinfle domain antibody: Mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 2005;95:1201-1214.
90. Mena I, Cotizias GC. Protein intake and treatment of Parkinson's disease with levodopa. New Engl J Med 1975;292:181-184.
91. Cornford EM, Young D, Paxton JW, Finlay GJ, Wilson WR, Pardridge WM. Melphalan penetration of the blood-brain barrier via the neutral aminoacid transporter in tumor-bearing brain. Cancer Res 1992;52:138-143.
92. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999;8:775-782.
93. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Kamen BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-3401.
94. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-198.
95. Sadasivan E, da Costa M, Rothenberg SP, Brink L. Purification, properties, and immunological characterization of folate-binding proteins from human leukemia cells. Biochim Biophys Acta 1987;925:36-47.
96. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-2443.
97. Franklin WA, Waintrub M, Edwards D, Christensen K, Prendegrast P, Woods J, Bunn PA, Kolhouse JF. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl 1994;8:89-95.
98. Nakashima-Matsushita N, Homma T, Yu S, Matsuda T, Sunahara N, Nakamura T, Tsukano M, Ratnam M, Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1609-1616.
99. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56:1205-1217.
100. Boyle JJ. Macrophage activation in atherosclerosis: Pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005;3:63-68.
101. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci 2005;94:2135-2146.
102. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-293.
103. Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 2004;56:1099-1109.
104. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067-1084.
105. Turek JJ, Leamon CP, Low PS. Endocytosis of folate-protein conjugates: Ultrastructural localization in KB cells. J Cell Sci 1993;106:423-430.
106. Leamon CP, DePrince RB, Hendren RW. Folate-mediated drug delivery: Effect of alternative conjugation chemistry. J Drug Target 1999;7:157-169.
107. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004 11:996-1004.
108. Stella B, Arpicco S, Peracchia MT, Desmaele D, Hoebeke J, Renoir M, D'Angelo J, Cattel L, Couvreur P. Design of folic acid conjugated nanoparticles for drug targeting. J Pharm Sci 2000;89:1452-1464.
109. Salmaso S, Semenzato A, Caliceti P, Hoebeke J, Sonvico F, Dubernet C, Couvreur P. Specific antitumor targetable beta-cyclodextrin-poly(ethylene glycol)-folic acid drug delivery bioconjugate. Bioconjug Chem 2004;15:997-1004.
110. Majoros IJ, Thomas TP, Mehta CB, Baker JR. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem 2005;48:5892-5899.
111. Dube D, Francis M, Leroux JC, Winnik FM. Preparation and tumor cell uptake of poly(N-isopropylacrylamide) folate conjugates. Bioconjug Chem 2002;13:685-692.
112. Caliceti P, Salmaso S, Semenzato A, Carofiglio T, Fornasier R, Fermeglia M, Ferrone M, Pricl S. Synthesis and physicochemical characterization of folate-cyclodextrin bioconjugate for active drug delivery. Bioconjug Chem 2003;14:899-908.
113. Liu J, Kolar C, Lawson TA, Gmeiner WH. Targeted drug delivery to chemoresistant cells: Folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells. J Org Chem 2001;66:5655-5663.
114. Lee JW, Lu JY, Low PS, Fuchs PL. Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. Bioorg Med Chem 2002;10:2397-2414.
115. Steinberg G, Borch RF. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. J Med Chem 2001;44:69-73.
116. Ladino CA, Chari RV, Bourret LA, Kedersha NL, Goldmacher VS. Folate-maytansinoids: Target-selective drugs of low molecular weight. Int J Cancer 1997;73:859-864.
117. Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain. J Biol Chem 1993;268:24847-24854.
118. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003;92:49-67.
119. Aronov O, Horowitz AT, Gabizon A, Gibson D. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug Chem 2003;14:563-574.
120. Leamon CP, Cooper SR, Hardee GE. Folate-liposome-mediated antisense oligodeoxy-nucleotide targeting to cancer cells: Evaluation in vitro and in vivo. Bioconjug Chem 2003;14:738-747.
121. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci USA 1995;92:3318-3322.
122. Qualls MM, Thompson DH. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: Intracellular localization and synergistic phototoxicity. Int J Cancer 2001;93:384-392.
123. Schneider R, Schmitt F, Frochot C, Fort Y, Lourette N, Guillemin F, Muller JF, Barberi-Heyob M. Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorg Med Chem 2005;13:2799-2808.
124. Turk MJ, Waters DJ, Low PS. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 2004;30; 213:165-172.